You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 295 No. 23, June 21, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Ophthalmology
 •Cataracts/ Lens
 •Adverse Effects
 •Alert me on articles by topic

Statin Use and Incident Nuclear Cataract

Barbara E. K. Klein, MD, MPH; Ronald Klein, MD, MPH; Kristine E. Lee, MS; Lisa M. Grady, BS

JAMA. 2006;295:2752-2758.

Context  Statins are widely prescribed for their lipid-lowering effects but also have putative antioxidant properties. Oxidative stress is believed to play a role in the development of nuclear cataract, but little is known regarding the relationship of statin use and cataract incidence.

Objective  To evaluate the relationship of use of statins and incident cataract in adults in a midwestern community in the United States.

Design, Setting, and Participants  The Beaver Dam Eye Study, an observational, longitudinal, population-based study of age-related eye disease in Beaver Dam, Wis. There were 1299 persons who were seen at the third examination in 1998-2000, had gradable photographs in both eyes, and were deemed to be at risk of developing nuclear cataract within 5 years.

Main Outcome Measure  Five-year incidence of cataract with respect to statin use. Cataracts were graded from photographs taken through the participant’s dilated pupil.

Results  A total of 210 persons developed incident nuclear cataract in the interval from 1998-2000 to 2003-2005. Five-year incidence of nuclear cataract was 12.2% in statin users compared with 17.2% in nonusers (odds ratio [OR], 0.55; 95% confidence interval [CI], 0.36-0.84), controlling for age. When only never smokers without diabetes were assessed, the age-, lipid level–, and sex-adjusted OR was 0.40 (95% CI, 0.18-0.90). Five-year incidence of cortical cataract was 9.9% in statin users and 7.5% in nonusers (OR, 1.28; 95% CI, 0.79-2.08); posterior subcapsular cataract occurred in 3.0% of statin users and 3.4% of nonusers (OR, 0.82; 95% CI, 0.39-1.71).

Conclusion  Statin use in a general population appears to be associated with lower risk of nuclear cataract, the most common type of age-related cataract.


Author Affiliations: Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health, Madison.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lovastatin Inhibits TGF-{beta}-Induced Myofibroblast Transdifferentiation in Human Tenon Fibroblasts
Meyer-ter-Vehn et al.
IOVS 2008;49:3955-3960.
ABSTRACT | FULL TEXT  

Nuclear Cataract: Do Statins Reduce Risk?
Leske
Arch Ophthalmol 2007;125:401-402.
FULL TEXT  

Might Statins Prevent Cataracts?
Journal Watch Cardiology 2006;2006:5-5.
FULL TEXT  

What's new in the other general journals.
Tonks
BMJ 2006;333:37-38.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.